


Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A composition of matter of the formula



and multimers thereof, wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

P^1 , P^2 , P^3 , and P^4 are each independently randomized EPO-mimetic antagonist peptide sequences;

L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1 and wherein "peptide" refers to molecules 2 to 40 amino acid and wherein neither X^1 nor X^2 is a native protein.


2. (original) The composition of matter of Claim 1 of the formulae




or



3. (original) The composition of matter of Claim 1 of the formula



4. (original) The composition of matter of Claim 1 of the formula



5. (original) The composition of matter of Claim 1 wherein F^1 is an IgG Fc domain.

6. (original) The composition of matter of Claim 1 wherein F^1 is an IgG1 Fc domain.

7. (original) The composition of matter of Claim 1 wherein F^1 comprises the sequence of SEQ ID NO: 2.

- 8-12. (canceled)

13. (previously presented) The composition of matter of Claim 1 wherein the EPO mimetic peptide sequence is selected from Table 5.
14. (previously presented) The composition of matter of Claim 13 wherein F¹ comprises the sequence of SEQ ID NO: 2.
15. (previously presented) The composition of matter of Claim 1 comprising a sequence selected from SEQ ID NOS: 83, 84, 85, 124, 419, 420, 421, and 41.
16. (previously presented) The composition of matter of Claim 1 comprising a sequence selected from SEQ ID NOS: 339 and 340.
- 17 - 66 (canceled).